CD200 Antibody, anti-mouse, REAfinity™
Synonyms: OX-2 membrane glycoprotein, MRC OX-2, Mox2
RECOMBINANT
Clone:
REA1279 | OX-90
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon
MICS (MACSima Imaging Cyclic Staining) applications
PE
Fixation:
frozen – PFA
Species tested:
mouse
Tissue used:
spleen
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-141-914
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a mouse spleen cryosection fixed with 4% PFA. The section was stained using CD200 Antibody, anti-mouse, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue).Scale bar: 30 µm.

Application image
Specifications for CD200 Antibody, anti-mouse, REAfinity™
Overview

Clone REA1279 recognizes the mouse CD200 antigen, which is a transmembrane glycoprotein containing two extracellular immunoglobulin domains and lacks intracellular signaling motifs or docking sites for adapter signaling molecules. CD200, also known as MRC OX-2 antigen, is expressed on a variety of tissues, including the nervous system, activated T-cells, B-cells, and endothelial cells. CD200 interacts with CD200R, an immunoglobulin superfamily inhibitory receptor expressed primarily on myeloid/monocyte lineage cells to regulate myeloid cell activity. Furthermore it has a suppressive effect on T cell–mediated immune response.

Additional information: Clone REA1279 displays negligible binding to Fc receptors.

Alternative names

OX-2 membrane glycoprotein, MRC OX-2, Mox2

Detailed product information

Technical specifications

Clone
REA1279
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody, human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
mouse
Antigen
CD200
Distribution of antigen
B cells, T cells, endothelial cells, other

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD200 Antibody, anti-mouse, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD200 Antibody, anti-mouse, REAfinity™
Publications
  1. Zhang, S. et al. (2004) Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173 (11): 6786-6793
  2. Barclay, A. N. et al. (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 23 (6): 285-290

You have previously chosen International as your location.
What do you want to do?